Testing NB003 for advanced GIST after prior treatments
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called NB003 for people with advanced GIST (a type of stomach or intestinal tumor) that has stopped responding to or could not be tolerated after standard treatments like imatinib or sunitinib. The goal is to see if NB003 can help shrink or control the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced GIST that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor has a change in the KIT gene (a specific mutation).
- You have tried imatinib (and for one part of the study, sunitinib) and it no longer works or caused side effects you couldn't handle.
- You have at least one measurable tumor on a scan.
- You are in good enough health to be up and about (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called KQB198 combined with imatinib for people with advanced or metastatic gastrointestinal stromal tumor (GIST) that has a specific KIT or PDGFRA mutation. The goal is to see if this combination works better than imatinib alone as a first treatment.
This study tests a combination of two drugs (regorafenib and envafolimab) for gastrointestinal stromal tumors (a type of stomach/bowel cancer) that have stopped responding to standard treatments. The trial compares this combination to other doctor-selected treatments to see if it slows tumor growth.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This study uses a blood test (ctDNA) to look for specific tumor DNA changes, then guides treatment with sunitinib or regorafenib in people with GIST that has spread or cannot be removed by surgery. It aims to see whether this ctDNA-guided approach improves outcomes compared with standard decision-making.
This study tests a combination of two drugs—regorafenib (a targeted therapy) and envafolimab (an immunotherapy)—for people with advanced GIST whose tumors have a specific KIT gene mutation (exon 17) and have stopped responding to standard treatments.
Hear when a new Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.